Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent in the European Union, or EU, to treat severe atopic dermatitis in children aged six months to five years old who are candidates for systemic therapy. With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
- Regeneron price target lowered to $802 from $806 at RBC Capital
- Regeneron, Sanofi present results from Dupixent clinical trial
- Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
- Regeneron pressure from CMS draft a buying opportunity, says Morgan Stanley